Protego to Highlight PROT-001's Potential to Target Light Chain Toxicity in AL Amyloidosis at ISA 2026

- Phase 1 results in healthy volunteers characterize the clinical profile of PROT-001, an investigational first-in-class lambda light chain kinetic stabilizer - Preclinical presentations to evaluate PROT-001's potential to reduce light chain-induced cardiac toxicity in AL amyloidosis and...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.